TRK inhibitor in a patient with metastatic triple-negative breast cancer and <i>NTRK</i> fusions identified <i>via</i> cell-free DNA analysis
Arielle J. Medford(Harvard University), Aditya Bardia(UCLA Health), Laura M. Spring(Massachusetts General Hospital), Bariş Boyraz(Harvard University), Tasos Gogakos(Rockefeller University), Phoebe Ryan(Harvard University), Leif W. Ellisen(Harvard University), Charles S. Dai(Harvard University), Lesli A. Kiedrowski(Guardant (United States)), Jennifer C. Keenan(Massachusetts General Hospital), Jochen K. Lennerz(Addgene), Lauren Oshry(Boston Medical Center), Sofia Menshikova(Addgene), Rachel O. Abelman(Massachusetts General Hospital), Anna Butusova(Addgene), Beverly Moy(Global Cancer Institute)
Cited by 11
Related Papers
Circulating Tumor Cell Clusters Are Oligoclonal Precursors of Breast Cancer Metastasis
|Cell|2014|2.5k
Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition
|Science|2013|2.5k
Inertial Focusing for Tumor Antigen–Dependent and –Independent Sorting of Rare Circulating Tumor Cells
|Science Translational Medicine|2013|1.1k
Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer
|New England Journal of Medicine|2019|1k